A

nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. We have a modest agenda that includes catching up with family and friends, and hopefully, our reading, as well. A few naps are also envisioned. And what about you? This is a lovely time of year to explore the great outdoors. Those of you with a sense of adventure could mosey among garage sales seeking hard-to-find treasures. Or you could simply plan the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Pfizer is offering its Ibrance breast cancer drug free to the UK National Health Service while cost regulators decide if it should be routinely funded, PharmaTimes says us. The drug was approved last November as a first-line treatment, but in February, the National Institute for Health and Care Excellence rejected the drug, which costs nearly $100,000, after concluding trial data could not quantify progression-free survival.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.